Proteostasis Therapeutics Inc (PTI.OQ)
16 Aug 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|74||2016||Independent Chairman of the Board|
|44||2014||President, Chief Executive Officer, Director|
|44||2018||Chief Operating Officer|
|47||Executive Vice President, Chief Medical Officer|
|55||2017||Chief Scientific Officer|
- BRIEF-Proteostasis Announces Formation Of Independent Steering Committee To Advise On Global Phase 3 Clinical Development Program For Pti-428 In Cystic Fibrosis
- BRIEF-Proteostasis Therapeutics Says CFO Helen Boudreau Provided Notice Of Resignation
- BRIEF-Proteostasis Therapeutics - Co & Astellas Pharma Entered Into Amendment No. 6 To Collaboration & License Agreement
- BRIEF-Proteostasis Receives Endorsement From Cystic Fibrosis Foundation For Study Of PTI-428 In CF Subjects On Background Symdeko Therapy
- BRIEF-Proteostasis Therapeutics Files For Mixed Shelf Of Up To $100 Mln